These investments are enabling faster, more efficient geographic and product expansion, more valuable customer interactions and deeper platform engagement," Dudum told investors
A dose of experimental hormesis: When mild stress protects and improves animal performance
CagriSema produced unprecedented mean weight loss of 20.4% at 68 weeks on an intent-to-treat basis, significantly exceeding semaglutide alone (14.9%), cagrilintide alone (11.5%), and placebo (3.0%)
#Semaglutide #Ozempic #NatcoPharma #Generics #PharmaIndia #DiabetesCare #GLP1 To view or add a comment, sign in Lillys new weight-loss pill gets US approval, intensifies rivalry with Novo Nordisk A major development in the obesity treatment space
It primarily works by mimicking a hormone in the body (GLP-1), targeting areas of the brain that regulate appetite and food intake